Micrometastases in neuroblastoma: Are they clinically important?

Journal of Clinical Pathology

Volumn 57, Issue 1, 2004, Pages 14-20

  Burchill, S A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE;

BONE MARROW METASTASIS; BRAIN METASTASIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CATECHOLAMINE SYNTHESIS; CYTODIAGNOSIS; CYTOPATHOLOGY; GENE EXPRESSION PROFILING; GENETIC RISK; HUMAN; ION PAIR CHROMATOGRAPHY; NEUROBLASTOMA; ONCOGENE C MYC; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STATISTICAL SIGNIFICANCE;

BONE MARROW NEOPLASMS; GENETIC TECHNIQUES; HUMANS; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; NEUROBLASTOMA;

EID: 0348062816     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.57.1.14     Document Type: Review

References (50)

1. Bolande RP. The spontaneous regression of neuroblastoma. Experimental evidence for a natural host immunity. Pathol Annu 1991;26:187-99.
2. Wilson LM. Neuroblastoma, its natural history and prognosis: a study of 487 cases. BMJ 1974;3:301-7.
3. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
4. Cheung NK, Heller G, Kushner BH, et al. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 1997;8:2807-17.
5. Reid MM, Pearson ADJ. Bone marrow infiltration in neuroblastoma. Lancet 1991;337:681-2.
6. Favrot MC, Frappaz D, Maritax O, et al. Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer 1986;54:637-41.
7. Cheung NK, Von Hoff DD, Strandjord SE, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-9.
8. Rogers DW, Treleaven JG, Kemshead JT, et al. Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma. J Clin Pathol 1989;42:422-6.
9. Carey PJ, Thomas L, Buckle G, et al. Immunocytochemical examination of bone marrow in disseminated neuroblastoma. J Clin Pathol 1990;43:9-12.
10. Moss TJ, Cairo M, Santana VM, et al. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 1994;83:3085-9.
11. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol 1990;8:736-40.
12. Faulkner LB, Tintori V, Tamburini A, et al. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. J Hematother 1998;4:361-6.
13. Komada Y, Zhang XL, Zhou YW, et al. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998;82:591-9.
14. Nogai J, Ishida Y, Koga N, et al. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hemotol Oncol 2000;22:20-6.
15. Sze Tsang K, Kong Li C, Chiu Tsoi W, et al. Detection of micro-metastases of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase- polymerase chain reaction. Cancer 2003;97:2887-97.
16. Burchill SA, Selby P. Early detection of small volume disease using molecular technology. Cancer Topics 1999;10:1-4.
17. Burchill SA, Selby PJ. Molecular detection of low-level disease in patients with cancer. J Pathol 2000;190:6-14.
18. Kuroda T, Saeki M, Nakano M, et al. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. J Pediatr Surg 1997;32:69-72.
19. Gilbert J, Norris MD, Marshall GM, et al. Low specificity of PGP9.5 expression for detection of micro-metastatic neuroblastoma. Br J Cancer 1997;75:1779-81.
20. Miyajima Y, Kato K, Numata S, et al. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1995;75:2757-61.
21. Burchill SA, Bradbury FM, Lewis IJ. Early clinical evaluation of reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase. Eur J Cancer 1995;31:553-6.
22. Cheung IY, Cheung NK. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE. Med Pediatr Oncol 2001;36:210-12.
23. Cheung IY, Barber D, Cheung N. Detection of microscopic neuroblastoma in marrow by histology, immunocytology and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998;4:2801-5.
24. Lode HN, Handgretinger R, Schuermann U, et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 1997;33:2024-30.
25. Burchill SA, Lewis IJ, Abrams KR, et al. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator. J Clin Oncol 2001;19:1795-801.
26. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001;7:1698-705.
27. Pession A, Libri V, Sartini R, et al. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma. Oncol Rep 2003;10:357-62.
28. Lambooy LHJ, Gidding CEM, van den Heuvel LP, et al. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma. Clin Cancer Res 2003;9:812-19.
29. Träger C, Kogner P, Lindskog M, et al. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003;49:104-12.
30. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197:461-3.
31. Mehes G, Luegmayr A, Kornmuller R, et al. Detection of disseminated tumor cells in neuroblastoma: 3 log improvement in sensitivity by automatic immunofluorescence plus FISH (AIPF) analysis compared with classical bone marrow cytology. Am J Pathol 2003;163:393-9.
32. Ross AM. Minimal residual disease in solid tumour malignancies: a review. J Hematother 1998;7:9-18.
33. Moss TJ. Clinical relevance of minimal residual cancer in patients with solid malignancies. Cancer Metastasis Rev 1999;18:91-100.
34. Moss T, Rynolds C, Sather H, et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-26.
35. Horibe K, Fukuda M, Miyajima Y, et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 2001;36:203-4.
36. Fukuda M, Horibe K, Furukawa K. Enhancement of in vitro and in vivo antitumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. Int J Mol Med 1998;2:471-5.
37. Shono K, Tajiri T, Fujii Y, et al. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. J Pediatr Surg 2000;35:1415-20.
38. Gao Y, Li G, Zhang X, et al. Detection of neuroblastoma cells in blood by reverse transcriptase-polymerase chain reaction. Chin Med J (Engl) 1997;110:341-5.
39. Miyajima Y, Horibe K, Fukuda M, et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of potients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 1996;77:1214-19.
40. Burchill SA, Kinsey SE, Roberts P, et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001;36:213-19.
41. 40a Burchill SA, Picton S, Wheeldon J, et al. Reduced tumour load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumours of the Ewing sarcoma family but not neuroblastoma. Blood 2003;102:1-2.
42. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 1993;342:1134-7.
43. Rill DR, Santana VM, Roberts WM, et al. Direct demonstration that autologous bone marrow transplantation for solid tumours can return a multiplicity of tumorigenic cells. Blood 1994;84:380-3.
44. Atra A, Pinkerton R. Autologous stem cell transplantation in solid tumours of childhood. Ann Med 1996;28:159-64.
45. Handgretinger R, Greil J, Schurmann U, et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997;6:235-42.
46. Tchirkov A, Kanold J, Giollant M, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998;30:228-32.
47. Leung W, Chen AR, Klann, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998;22:971-9.
48. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-CIS-retinoic acid. N Engl J Med 1999;341:1165-73.
49. Villablanca JG, Khan AA, Avramis VI, et al. Phase 1 trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 1995;13:894-901.
50. Manzke O, Russello O, Leenen C, et al. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Med Pediatr Oncol 2001;36:185-9.